State-of-the-Art Transdermal Drug Delivery Patents From Vyteris to be Sold via Global Online Sale by Heritage Global Partners June 27-28

By May 29, 2013Press Releases

(Dow Jones and Company, Inc.) May 29 10:22 AM EDT

State-of-the-Art Transdermal Drug Delivery Patents From Vyteris to be Sold via Global Online Sale by Heritage Global Partners June 27-28 SAN DIEGO & FOSTER CITY, Calif.–(BUSINESS WIRE)–May 29, 2013–

Heritage Global Partners (“HGP”), a global leader in asset advisory and auction services and a wholly owned subsidiary of Counsel RB Capital (OTCQB: CRBN), today announced, Subject to US Bankruptcy Court Approval, its upcoming global online sale of more than 25 state-of-the-industry transdermal drug delivery patents from Vyteris, Inc.

Vyteris’ patented active patch system avoids or minimizes many of the shortcomings and issues typically associated with conventional drug delivery methods. The system delivers drugs comfortably through the skin using low-level electrical energy that sends the drug directly to the bloodstream, thereby avoiding the liver, and reducing stomach and gastrointestinal issues for the patient, which can often be associated with oral drug administrations.

Active patch technology also allows precise dosing, giving physicians and patients control over the rate, dosage, and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over other methods of drug administration. The system is also convenient to use, providing a relatively pain-free application, ultimately delivering the drug automatically and lessening concerns about patient compliance.

The global online patent sale is scheduled to launch at 10 am PT on June 27, 2013 and closes June 28 at 10 am PT. Interested potential bidders are strongly encouraged to visit the Virtual Data Room by contacting Nick Dove (contact info below). Online visitors can also click on Vyteris Sale for more information.

“Vyteris’ transdermal drug delivery technology can be successfully utilized for the delivery of numerous drugs, including many peptides, which until now, typically necessitated injections or intravenous infusions,” stated Nick Dove, Director of Sales at Heritage Global Partners. “We expect a very strong response from prospective participants and bidders that are interested in this unprecedented opportunity to acquire more than 25 unique, state-of-the-industry transdermal drug delivery patents.”

Led by auction industry pioneers Ross and Kirk Dove, Heritage Global Partners is one of the leading worldwide asset advisory and auction services firms, assisting companies with buying and selling assets. HGP specializes in asset brokerage, inspection, and valuations, industrial equipment and real estate auctions, and much more.

CONTACT:

Heritage Global Partners
Nick Dove, 858-847-0659
[email protected]

or

JCIR
Robert Rinderman or Jennifer Neuman, 212-835-8500
[email protected]